JUNSHI BIO Tables AGM Agenda: No 2025 Dividend, Up to RMB8.50 Billion Credit, RMB5.00 Billion Guarantee Quota and Fresh Mandates for Debt and Share Issuance

Shanghai-based biopharma developer JUNSHI BIO (01877) has released the circular for its 2025 Annual General Meeting to be held on 26 June 2026. Key proposals are summarised below:

Financials & Distribution • 2025 operating revenue rose 28.23 % to RMB2.50 billion, but the company recorded no distributable profit; the Board proposes no dividend or capitalisation issue for 2025.

Financing Arrangements • Management seeks authorisation to secure aggregate revolving credit lines of up to RMB8.50 billion from banks and other financial institutions for the 2026 financial year. • A separate special resolution requests a general mandate to issue domestic and overseas debt financing instruments of up to RMB2.50 billion (or foreign-currency equivalent), including short- and medium-term notes, corporate bonds and offshore bonds.

Guarantees • The Board proposes an estimated external guarantee quota not exceeding RMB5.00 billion for 2026, covering wholly-owned and majority-owned subsidiaries such as Shanghai Junshi Biotechnology and Suzhou Junao Precision Medicine. Existing guarantees total RMB5.50 billion, equating to 91.20 % of latest audited net assets.

Equity Mandates • A general mandate is sought to issue additional A and/or H shares, or related securities, up to 20 % of total issued shares (excluding treasury shares) within 12 months after the AGM.

Board & Governance • Prof. Chen Liang is nominated as an independent non-executive director. • Directors’ remuneration structure for 2026 will continue to combine fixed pay, performance-linked components and long-term incentives. • Deloitte Touche Tohmatsu and RSM China are proposed as 2026 auditors for Hong Kong and PRC reporting, respectively.

Connected Transaction • The company will contribute intellectual property and assets appraised at RMB53.08 million to Shanghai OnTarget Biopharmaceuticals in exchange for RMB0.25 million new registered capital, realising an estimated RMB52.12 million gain. The deal constitutes a connected transaction as non-executive director Dr. Yao Sheng is a shareholder of the JV.

Other Items • Shareholders will vote on a three-year (2026-2028) dividend policy framework, remuneration policies for directors and senior management, and a mandate to issue domestic and/or overseas debt financing instruments. • Equity restructuring of subsidiary Junyan Hongshi will convert it from a wholly-owned to a majority-owned unit, with no change to the use of proceeds from the 2022 A-share fundraising.

All resolutions will be decided by poll at the AGM; the H-share register will close from 23 to 26 June 2026.